Aveanna Healthcare Holdings Inc. · NASDAQ:AVAH
Aveanna Healthcare — Investor Presentation (January 2026)
25 slides from Aveanna Healthcare's investor presentation, Jan 14, 2026
Slide 1: Investor Presentation January 2026
Investor Presentation January 2026
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This investor presentation (this "presentation“) and any oral statements made in connection with this presentation are for information purposes only and do not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase a
Slide 3: Transforming the Value of Homecare
Transforming the Value of Homecare Aveanna offers a leading, diversified homecare platform that delivers innovative care to pediatric, adult, and geriatric patients. With locations in 38 states, Aveanna has established a national footprint dedicated to high-quality clinical outcomes and enhanced val
Slide 4: Management Team
Debbie Stewart Principal Accounting Officer Jeff Shaner Chief Executive Officer CEO of Aveanna since 2023 Instrumental in formation of Aveanna Healthcare Chief Operating Officer of Aveanna Healthcare since 2017 Chief Operating Officer of PSA Healthcare since 2015 Former SVP, President of Operations
Slide 5: Aveanna Overview
Aveanna Overview 2025 Guidance Key Operating Statistics (3) $2.425b - $2.445b Revenue 33.7% Gross Margin(1) $318m - $322m Adjusted EBITDA 366 Locations 38 States 29,000 Caregivers 45m Homecare Hours(2) 93 Preferred Payors ___________________________ 1. 2025 Gross Margin for the nine-month period end
Slide 6: Aveanna's Transformative Homecare Platform
Melia and Mom Heather Valerie Aveanna's Transformative Homecare Platform Preferred Payor Partnerships Government Affairs Strategy Scaled National Platform Technology and Data Driven Results Reduction in Total Cost of Care Our advanced homecare platform positions us to improve outcomes with data-driv
Slide 7: Aveanna's Transformative Homecare Platform
Aveanna's Transformative Homecare Platform PDS Preferred Payors State Rate Increases Home Health Episodic Mix Value-based Agreements Continued substantial progress as demonstrated by key performance metrics. (1) ___________________________ 1. See Disclaimers and Forward-looking Statements slide. Pro
Slide 8: Aveanna's Transformative Homecare Platform: Long-term Growth Rate
Melia and Mom Heather Valerie Our future opportunity will continue to provide enhanced value that is driven by our significant investment in our value-based national homecare platform. Aveanna's Transformative Homecare Platform Value-based Organic Growth Risk-based Growth Core Organic Growth Scaled
Slide 9: Aveanna Business Segments
Valerie Melia and Mom Heather Aveanna Business Segments
Slide 10: Private Duty Services Segment
Private Duty Services Segment Financial Highlights Key Operating Statistics (4) $1,947m Net Revenue1 26% – 28% Gross Margin2 3% – 5% Organic Growth Rate3 257 Locations 29 States 39,000 Patients on Service 56% % of PP Volume Preferred Payors 30 Preferred Payor Partnerships underpinned by enhanced rat
Slide 11: Home Health & Hospice Segment
Home Health & Hospice Segment Financial Highlights Key Operating Statistics (4) Locations States Patients on Service Episodic Mix Preferred Payors $239m Net Revenue1 50% – 52% Gross Margin2 5% – 7% Organic Growth Rate3 82 15 13,850 45 Home Health Geriatric Patient Population Intermittent Services Sh
Slide 12: Medical Solutions Segment
Medical Solutions Segment Financial Highlights Key Operating Statistics (4) States we deliver to Patients on Service Preferred Payors $175m Net Revenue1 42% – 44% Gross Margin2 8% – 10% Organic Growth Rate3 27 30,300 18 Nutritional Support – Enteral Product, Equipment, and Supplies Provided to Pedia
Slide 13: Scaled Platform Built for Driving Growth and Enhancing Value
Scaled Platform Built for Driving Growth and Enhancing Value
Slide 14: Fragmented Home Care Markets Support Sustainable Growth
Fragmented Home Care Markets Support Sustainable Growth $20bn Legacy Pediatric Focus Personal Care $18.0bn Annual U.S. Healthcare Spend $4.5tn Therapy $6.0bn Enteral Nutrition $3.0bn Therapy $7.0bn Private Duty Nursing $10.0bn Hospice $23.0bn $99bn Addressable Adult Opportunity TAM Estimated annual
Slide 15: Q3 2025 Financial Performance: Summary Results
Q3 2025 Financial Performance: Summary Results PDS Q3 2025 revenue growth of 25.6% from Q3 2024, driven by 11.8 million hours of care or 12.9% YOY volume increase MS gross margin improvement of 140 bps as of the nine months ended September 27, 2025, compared to the same period 2024, driven by modern
Slide 16: Financial Performance: Capital Structure
Financial Performance: Capital Structure Liquidity of $478.7m, comprised of the following: $145.9m cash on balance sheet $227m revolver availability $105.8m securitization availability Undrawn revolver $23m in outstanding letters of credit Total variable rate debt of $1,490m, consisting of: First Li
Slide 17: Updated 2025 Guidance
Updated 2025 Guidance Previous Revenue Guidance: Greater than $2.375 billion Increased 2025 Revenue Guidance to a range of: $2.425 billion to $2.445 billion ___________________________ See appendix for reconciliation of guidance Net Income to Adjusted EBITDA for the fiscal year ended January 3, 2026
Slide 18: 2025 Guidance Adjusted EBITDA Bridge
2025 Guidance Adjusted EBITDA Bridge ___________________________ (1) See Appendix for reconciliation of guidance net income to Adjusted EBITDA and Normalized Adjusted EBITDA for the fiscal year ended January 3, 2026. (2) Represents the midpoint of the guidance Adjusted EBITDA range for the fiscal ye
Slide 19: 2026 Guidance
2026 Guidance 2026 Revenue Guidance range of: $2.54 billion to $2.56 billion 2026 Adjusted EBITDA Guidance range of: $318 million to $322 million ___________________________ Consistent with prior practice, we are not providing guidance on net income for fiscal year 2026 (year ending January 2, 2027)
Slide 20: Path Forward: Strategic and Operational Focus on Driving Shareholder Value
Path Forward: Strategic and Operational Focus on Driving Shareholder Value Value-based Growth Enhanced Capital Structure Core Organic Growth
Slide 21: Appendix
8 aveanna healthcare: Appendix Zi
Slide 22: Non-GAAP Measures
Non-GAAP Measures Non-GAAP Financial Measures In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), we also evaluate our financial performance using EBITDA, Adjusted EBITDA, Normalized Adjusted EBITDA, Field contribution and
Slide 23: Reconciliation of Net Income to Adjusted EBITDA
Reconciliation of Net Income to Adjusted EBITDA ___________________________ 1-7 and A: Please see our financial filings (10K, 10Q) for 2023, 2024 and Q3 2025 for further description of the nature of these items
Slide 24: Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
Slide 25: Reconciliation of Guidance Net Income to Adjusted EBITDA and Normalized Adjusted EBITDA
Reconciliation of Guidance Net Income to Adjusted EBITDA and Normalized Adjusted EBITDA (1) Income tax benefit is driven by the anticipated partial release of a deferred tax asset valuation allowance during the fiscal year ended January 3, 2026. (2) Represents valuation adjustments and settlements a
Aveanna Healthcare Holdings — Investor Presentation (January 2026) on 6ix